Abcam, ab265770, Human SETD7 (SET7) knockout HeLa cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
SETD7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2,
Antibiotic resistance:Puromycin 1µg/mL,
Disease:Adenocarcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-SETD7, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
SET7 also known as SETD7 or KMT7 is a lysine methyltransferase that adds methyl groups to lysine residues on target proteins influencing their function and stability. This protein has a molecular mass of approximately 55 kDa. SET7 is expressed in a variety of tissues including the heart liver and pancreas suggesting its versatile role across different biological systems.
Biological function summary
SET7 contributes to gene regulation by methylating histone H3 at lysine 4 (H3K4) a mark generally associated with transcriptional activation. It also methylates non-histone proteins such as p53 TAF10 and STAT3 affecting their activity and interactions. SET7 operates distinctively and does not need to be part of any complex to fulfill its function effectively in diverse cellular processes.
Pathways
SET7 modulates transcriptional pathways such as the p53 signaling pathway and the NF-kB pathway. It interacts with the p53 protein affecting cell cycle regulation and the response to DNA damage. The modification of NF-kB by SET7 can influence inflammation and immune responses. Through these pathways SET7 plays a role in maintaining cellular homeostasis and response to stress.
SET7 is involved in conditions like cancer and cardiovascular diseases. Its methylation of p53 links it to tumor suppression activities while its impact on NF-kB relates to inflammatory responses. Dysregulation of SET7 activity can lead to abnormal cell proliferation and inflammation pointing to its potential as a target for therapeutic intervention.